2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare access
2016
High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA, Li P, Huo H, Pettit AR, Kumar R, Weiss BM, Huntington SF. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. The American Journal Of Managed Care 2016, 22: s78-86. PMID: 27270157.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsHigher cost sharingMedicare Part DDrug initiationMyeloid leukemiaLIS patientsInitiation of TKIsRetrospective claims-based analysisOral tyrosine kinase inhibitorNon-LIS patientsMonths of diagnosisClaims-based analysisPart DLow-income subsidyTKI claimsD patientsCox regressionMedicare claimsPatientsCritical therapyBenefit phasePocket costsSpecialty drugsCost sharing